Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.

One of these is the 5-HT2A receptor, which has a recently discovered unique characteristic: It dampens incoming visual information, giving our brain more space for internal processes and ...

(NASDAQ:DRUG) is a biotechnology company that develops 5-HT2A and 5-HT2C serotonin receptor agonists to treat epilepsy, pain, depression, and PTSD. It leverages its proprietary platform to target ...

We propose a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. A diverse sample with regard to ethnoracial identity and SES will be ...

Most psychedelic research has focused on a different receptor (5-HT2A), which is what makes them cause hallucinations. But scientists believe 5-HT1A might be a key player in developing better ...

A study reveals distinct brain circuits that psychedelics activate to reduce anxiety without causing hallucinations in mice.

According to the partners, DSP-0038 combines serotonin 5-HT2A receptor antagonism and 5-HT1A receptor agonism – two well established targets for antipsychotic drugs – in a single small molecule.